干细胞培养条件和稳定性：PluriMes 联盟和多能干细胞平台联合研讨会。
Stem cell culture conditions and stability: a joint workshop of the PluriMes Consortium and Pluripotent Stem Cell Platform.
机构信息
International Stem Cell Banking Initiative, 2 High Street, Barley, Hertfordshire SG8 8HZ, UK.
Centre for Stem Cell Biology, Department of Biomedical Science, The University of Sheffield, Sheffield, S10 2TN, UK.
出版信息
Regen Med. 2019 Mar;14(3):243-255. doi: 10.2217/rme-2019-0001. Epub 2019 Apr 2.
Abstract
Human stem cells have the potential to transform medicine. However, hurdles remain to ensure that manufacturing processes produce safe and effective products. A thorough understanding of the biological processes occurring during manufacture is fundamental to assuring these qualities and thus, their acceptability to regulators and clinicians. Leaders in both human pluripotent and somatic stem cells, were brought together with experts in clinical translation, biomanufacturing and regulation, to discuss key issues in assuring appropriate manufacturing conditions for delivery of effective and safe products from these cell types. This report summarizes the key issues discussed and records consensus reached by delegates and emphasizes the need for accurate language and nomenclature in the scientific discourse around stem cells.
摘要
人类干细胞具有改变医学的潜力。然而，仍存在一些障碍需要克服，以确保制造过程能够生产出安全有效的产品。彻底了解制造过程中发生的生物学过程对于确保这些质量，从而确保监管机构和临床医生能够接受这些产品，是至关重要的。召集了人类多能干细胞和体细胞干细胞领域的领导者，以及临床转化、生物制造和监管方面的专家，共同讨论确保这些细胞类型有效和安全产品交付的合适制造条件的关键问题。本报告总结了讨论的关键问题，并记录了代表们达成的共识，强调了在干细胞科学论述中使用准确语言和术语的必要性。
相似文献
1
Stem cell culture conditions and stability: a joint workshop of the PluriMes Consortium and Pluripotent Stem Cell Platform.干细胞培养条件和稳定性：PluriMes 联盟和多能干细胞平台联合研讨会。
Regen Med. 2019 Mar;14(3):243-255. doi: 10.2217/rme-2019-0001. Epub 2019 Apr 2.
2
Science-based assessment of source materials for cell-based medicines: report of a stakeholders workshop.基于科学的细胞药物原材料评估：利益相关者研讨会报告
Regen Med. 2018 Dec;13(8):935-944. doi: 10.2217/rme-2018-0120. Epub 2018 Nov 29.
3
Culturing human pluripotent stem cells for regenerative medicine.培养人类多能干细胞用于再生医学。
Expert Opin Biol Ther. 2023 Jan-Jun;23(6):479-489. doi: 10.1080/14712598.2023.2225701. Epub 2023 Jun 23.
4
Large-scale expansion and exploitation of pluripotent stem cells for regenerative medicine purposes: beyond the T flask.大规模扩增和利用多能干细胞进行再生医学目的：超越 T 瓶。
Regen Med. 2012 Jan;7(1):71-84. doi: 10.2217/rme.11.101.
5
Pluripotent stem cells in regenerative medicine: challenges and recent progress.再生医学中的多能干细胞：挑战与最新进展。
Nat Rev Genet. 2014 Feb;15(2):82-92. doi: 10.1038/nrg3563.
6
Characterization of companion animal pluripotent stem cells.鉴定伴侣动物多能干细胞。
Cytometry A. 2018 Jan;93(1):137-148. doi: 10.1002/cyto.a.23163. Epub 2017 Jul 5.
7
Comparability: manufacturing, characterization and controls, report of a UK Regenerative Medicine Platform Pluripotent Stem Cell Platform Workshop, Trinity Hall, Cambridge, 14-15 September 2015.可比性：制造、特性鉴定与控制，英国再生医学平台多能干细胞平台研讨会报告，剑桥三一学院，2015年9月14 - 15日
Regen Med. 2016 Jul;11(5):483-92. doi: 10.2217/rme-2016-0053. Epub 2016 Jul 12.
8
Manufacturing with pluripotent stem cells (PSConf 2021): Key issues for future research and development.多能干细胞制造（PSConf 2021）：未来研究与开发的关键问题。
Cell Prolif. 2022 Aug;55(8):e13301. doi: 10.1111/cpr.13301.
9
Identification, characterization and biological significance of very small embryonic-like stem cells (VSELs) in regenerative medicine.在再生医学中，非常小的胚胎样干细胞（VSELs）的鉴定、特征描述和生物学意义。
Histol Histopathol. 2012 Jul;27(7):827-33. doi: 10.14670/HH-27.827.
10
GMP-compatible and xeno-free cultivation of mesenchymal progenitors derived from human-induced pluripotent stem cells.人诱导多能干细胞来源的间充质祖细胞的 GMP 兼容和无异种培养。
Stem Cell Res Ther. 2019 Jan 11;10(1):11. doi: 10.1186/s13287-018-1119-3.
引用本文的文献
1
The Effect of Stem Cell Secretome on the Improvement of Diabetic Wound Recovery: A Systematic Review and Meta-Analysis of In Vivo Studies.干细胞分泌组对改善糖尿病伤口愈合的影响：一项体内研究的系统评价和荟萃分析
Curr Ther Res Clin Exp. 2025 Feb 4;102:100778. doi: 10.1016/j.curtheres.2025.100778. eCollection 2025.
2
Neuronal cell-based medicines from pluripotent stem cells: Development, production, and preclinical assessment.基于多能干细胞的神经细胞药物：开发、生产和临床前评估。
Stem Cells Transl Med. 2021 Nov;10 Suppl 2(Suppl 2):S31-S40. doi: 10.1002/sctm.20-0522.
3
Process parameter development for the scaled generation of stem cell-derived pancreatic endocrine cells.规模化生成干细胞来源的胰腺内分泌细胞的工艺参数开发。
Stem Cells Transl Med. 2021 Nov;10(11):1459-1469. doi: 10.1002/sctm.21-0161. Epub 2021 Aug 13.
4
EBiSC best practice: How to ensure optimal generation, qualification, and distribution of iPSC lines.EBiSC 最佳实践：如何确保 iPSC 系的最佳生成、鉴定和分发。
Stem Cell Reports. 2021 Aug 10;16(8):1853-1867. doi: 10.1016/j.stemcr.2021.07.009.
5
Generation, functional analysis and applications of isogenic three-dimensional self-aggregating cardiac microtissues from human pluripotent stem cells.从人类多能干细胞中生成、功能分析和应用同基因三维自聚集心脏微组织。
Nat Protoc. 2021 Apr;16(4):2213-2256. doi: 10.1038/s41596-021-00497-2. Epub 2021 Mar 26.
6
[From the bench to the clinic: The challenge of translating platelet production in vitro].从实验室到临床：体外血小板生成转化面临的挑战
Bull Acad Natl Med. 2020 Dec;204(9):981-988. doi: 10.1016/j.banm.2020.10.004. Epub 2020 Oct 13.
7
A Defined and Scalable Peptide-Based Platform for the Generation of Human Pluripotent Stem Cell-Derived Astrocytes.一种用于生成人多能干细胞源性星形胶质细胞的定义和可扩展的肽基平台。
ACS Biomater Sci Eng. 2020 Jun 8;6(6):3477-3490. doi: 10.1021/acsbiomaterials.0c00067. Epub 2020 May 6.
本文引用的文献
1
Science-based assessment of source materials for cell-based medicines: report of a stakeholders workshop.基于科学的细胞药物原材料评估：利益相关者研讨会报告
Regen Med. 2018 Dec;13(8):935-944. doi: 10.2217/rme-2018-0120. Epub 2018 Nov 29.
2
Clear up this stem-cell mess.清理干细胞领域的这团乱麻。
Nature. 2018 Sep;561(7724):455-457. doi: 10.1038/d41586-018-06756-9.
3
Report of the international conference on manufacturing and testing of pluripotent stem cells.多能干细胞制造与测试国际会议报告
Biologicals. 2018 Nov;56:67-83. doi: 10.1016/j.biologicals.2018.08.004. Epub 2018 Aug 24.
4
Assessment of established techniques to determine developmental and malignant potential of human pluripotent stem cells.评估已建立的技术以确定人类多能干细胞的发育和恶性潜能。
Nat Commun. 2018 May 15;9(1):1925. doi: 10.1038/s41467-018-04011-3.
5
Lancet Commission: Stem cells and regenerative medicine.《柳叶刀》委员会：干细胞与再生医学
Lancet. 2018 Mar 3;391(10123):883-910. doi: 10.1016/S0140-6736(17)31366-1. Epub 2017 Oct 4.
6
Scientific considerations for the regulatory evaluation of cell therapy products.细胞治疗产品监管评估的科学考量
Biologicals. 2017 Nov;50:20-26. doi: 10.1016/j.biologicals.2017.08.011. Epub 2017 Sep 6.
7
Assessing the Safety of Human Pluripotent Stem Cells and Their Derivatives for Clinical Applications.评估人类多能干细胞及其衍生物用于临床应用的安全性。
Stem Cell Reports. 2017 Jul 11;9(1):1-4. doi: 10.1016/j.stemcr.2017.05.029.
8
Effect of cryopreservation on viability and growth efficiency of stromal-epithelial cells derived from neonatal human thymus.冷冻保存对源自新生儿胸腺的基质上皮细胞活力和生长效率的影响。
Cryobiology. 2017 Oct;78:70-79. doi: 10.1016/j.cryobiol.2017.06.010. Epub 2017 Jun 28.
9
"Mesenchymal stem cells": fact or fiction, and implications in their therapeutic use.“间充质干细胞”：事实还是虚构，及其在治疗应用中的意义
F1000Res. 2017 Apr 20;6. doi: 10.12688/f1000research.10955.1. eCollection 2017.
10
Predictive Markers Guide Differentiation to Improve Graft Outcome in Clinical Translation of hESC-Based Therapy for Parkinson's Disease.预测性标志物指导分化以改善基于人胚胎干细胞的帕金森病治疗临床转化中的移植物结局。
Cell Stem Cell. 2017 Jan 5;20(1):135-148. doi: 10.1016/j.stem.2016.09.004. Epub 2016 Oct 27.
Zotero 插件